News and Trends 14 Feb 2023 BiPER Therapeutics raises €1.25M to develop small molecules to treat gastrointestinal cancers BiPER Therapeutics, a French preclinical biotechnology company developing first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers, has raised €1.25 million ($1.35 million) in seed funding. BiPER Therapeutics received €300,000 in dilutive funds from WiSeed via WiClub Santé 2, €500,000 in convertible bonds from Bpifrance, and €450,000 in grants as part of the i-Lab […] February 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 14 Feb 2023 How efficient lab inventory management can become a driver for success Lab inventory management is often not the first priority of biotech companies trying to stay ahead in a competitive environment. But according to a report released by the EU commission, the hidden costs of inefficient lab practices are estimated to exceed €10B every year. Novel lab inventory management solutions can thus reduce costs and push […] February 14, 2023 - 5 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 FDA approves GSK drug for recurrent or advanced mismatch repair-deficient endometrial cancer GSK plc says the US Food and Drug Administration (FDA) has given full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not […] February 10, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Janssen reports positive topline phase 2 HDFN results The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the proof-of-concept phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition that can cause life-threatening anemia in the […] February 10, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Rocket Pharmaceuticals receives FDA RMAT designation for Danon disease gene therapy treatment Rocket Pharmaceuticals, Inc says the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RP-A501. RP-A501 is Rocket Pharmaceuticals’ investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon disease, a devastating and fatal genetic cardiac disease for which there are no disease-altering therapies available. RMAT designation was […] February 10, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […] February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Europe approves childhood epilepsy treatment UCB’s FINTEPLA (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. The approval by the European Commission (EC) was based on safety and efficacy data from a […] February 10, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas. 4basebio 4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in […] February 10, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline Sometimes, there’s an interview that we do that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer […] February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 9 Feb 2023 How AI and ML can transform clinical research By Gary Shorter, head of artificial intelligence at IQVIA Clinical trials are currently in an era of transformation through digitization, with much of the change being attributed to the integration of technologies such as natural language processing (NLP), artificial intelligence (AI), and machine learning (ML). Like many industries, health and life sciences are experiencing rapid […] February 9, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 New method to design new peptide therapeutics Researchers at Hokkaido University in Japan have developed a novel method to design and develop peptide antibiotics in large numbers, which could prove critical to controlling antibiotic resistance. Applications of new molecules as drugs are expected to be effective in treating diseases that are difficult to cure with currently used conventional drugs. Peptides are one […] February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Cell and Gene Therapy Catapult boost for life science campus The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of cell and gene therapies, has announced its involvement in the development of a major new campus for life science businesses in Stevenage. The new campus was announced by UBS Asset Management’s Real Estate & Private […] February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email